Provention Bio announced an addition to its leadership team on Tuesday.
The Oldwick-based biopharmaceutical company focused on immune-mediated diseases said it has appointed Sherron Kell as senior vice president of clinical development.
Kell will be responsible for leading the company’s PRV-031 (teplizumab) program, including oversight of its Phase 3 study and clinical support of anticipated regulatory submissions. She will report to Dr. Eleanor Ramos, chief medical and operating officer.
“The addition of Sherron further enhances our leadership team during a transformational time for Provention,” Provention Bio CEO Ashleigh Palmer said. “Sherron’s expertise and extensive clinical development experience will be invaluable as we execute our clinical and regulatory strategy for PRV-031 for the interception and prevention of T1D.”
Kell most recently served as vice president at Impax Pharmaceuticals, now Amneal Pharmaceuticals. Previously, she served as senior director, clinical R&D at Johnson & Johnson and scientific director at Novartis Pharmaceuticals.
